If a drug exhibits decreased hepatic clearance because of competitive inhibition with another co-administered medication, which consequence follows?

💡 Explanation

When hepatic clearance decreases due to competitive inhibition, the drug's elimination rate slows down, because the liver's capacity to metabolize the drug diminishes, therefore the drug remains in the body longer, leading to an increased plasma half-life, rather than a decreased half-life or altered volume of distribution.

• Why does skin blood flow increase when core body temperature rises above the hypothalamic set point during exercise?
• Which failure mode becomes likely when a patient with cirrhosis consumes excessive acetaminophen?
• If a woman experiences elevated levels of prolactin due to a pituitary adenoma while breastfeeding, which consequence is most likely?
• Why does excessive fibrinolysis increase the risk of hemorrhage following tissue plasminogen activator (tPA) administration for stroke?
• Why does severe dehydration cause rapid, potentially fatal, brain cell shrinkage in elderly patients, despite the plasma osmolality initially remaining within a near-normal range?
• Why does muscle fiber AP firing rate fail despite continued stimulation during high-intensity exercise?